Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors. Patients with advanced tumors refractory to prior stand...
Saved in:
| Published in | Journal of hematology and oncology Vol. 18; no. 1; pp. 15 - 10 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
07.02.2025
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors.
Patients with advanced tumors refractory to prior standard therapies were enrolled. In phase Ib, patients received LBL-007 200 mg or 400 mg and toripalimab 240 mg intravenously once every 3 weeks. In phase II, all patients received LBL-007 at the recommended phase II dose (RP2D) and toripalimab 240 mg intravenously once every 3 weeks. The primary end points were safety in phase Ib and objective response rate (ORR) in phase II. The exploratory end point was the predictive capability of LAG-3 and PD-L1 expression for efficacy.
Between November 30, 2021, and December 1, 2023, 80 patients were enrolled, including 30 (37.5%) with NPC and 50 (62.5%) with other tumors. Median follow-up was 26.0 months. In Phase Ib, LBL-007 was administered at 200 mg to four patients and 400 mg to six patients, with no dose-limiting toxicities observed. Therefore, the 400 mg dose of LBL-007 was established as the RP2D and administered to 70 patients in phase II. Nine (11.3%) of 80 patients had grade 3 or 4 treatment-related adverse events, the most common of which included anemia (2.5%), hyponatremia (2.5%), increased alanine aminotransferase (2.5%), increased aspartate aminotransferase (1.3%), and fatigue (1.3%). Eight patients (10.0%) had treatment-related serious adverse events. No treatment-related deaths were reported. In immunotherapy-naive NPC patients (n = 12), ORR was 33.3%, disease control rate (DCR) was 75%, and median progression-free survival (PFS) was 10.8 months (95% CI, 1.3 to not estimated). In IO-treated NPC patients (n = 17), ORR was 11.8%, DCR was 64.7%, and median PFS was 2.7 months (95% CI, 1.4 to 4.9). For other tumors, ORRs were 15.8% in immunotherapy-naive patients and 3.7% in immunotherapy-treated patients. Patients with ≥ 2 + LAG-3 expression had a higher ORR of 28.0%, compared to 7.7% in those with < 2 + LAG-3 expression.
LBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies. |
|---|---|
| AbstractList | PurposeOpen-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors.MethodsPatients with advanced tumors refractory to prior standard therapies were enrolled. In phase Ib, patients received LBL-007 200 mg or 400 mg and toripalimab 240 mg intravenously once every 3 weeks. In phase II, all patients received LBL-007 at the recommended phase II dose (RP2D) and toripalimab 240 mg intravenously once every 3 weeks. The primary end points were safety in phase Ib and objective response rate (ORR) in phase II. The exploratory end point was the predictive capability of LAG-3 and PD-L1 expression for efficacy.ResultsBetween November 30, 2021, and December 1, 2023, 80 patients were enrolled, including 30 (37.5%) with NPC and 50 (62.5%) with other tumors. Median follow-up was 26.0 months. In Phase Ib, LBL-007 was administered at 200 mg to four patients and 400 mg to six patients, with no dose-limiting toxicities observed. Therefore, the 400 mg dose of LBL-007 was established as the RP2D and administered to 70 patients in phase II. Nine (11.3%) of 80 patients had grade 3 or 4 treatment-related adverse events, the most common of which included anemia (2.5%), hyponatremia (2.5%), increased alanine aminotransferase (2.5%), increased aspartate aminotransferase (1.3%), and fatigue (1.3%). Eight patients (10.0%) had treatment-related serious adverse events. No treatment-related deaths were reported. In immunotherapy-naive NPC patients (n = 12), ORR was 33.3%, disease control rate (DCR) was 75%, and median progression-free survival (PFS) was 10.8 months (95% CI, 1.3 to not estimated). In IO-treated NPC patients (n = 17), ORR was 11.8%, DCR was 64.7%, and median PFS was 2.7 months (95% CI, 1.4 to 4.9). For other tumors, ORRs were 15.8% in immunotherapy-naive patients and 3.7% in immunotherapy-treated patients. Patients with ≥ 2 + LAG-3 expression had a higher ORR of 28.0%, compared to 7.7% in those with < 2 + LAG-3 expression.ConclusionLBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies. Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors.PURPOSEOpen-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors.Patients with advanced tumors refractory to prior standard therapies were enrolled. In phase Ib, patients received LBL-007 200 mg or 400 mg and toripalimab 240 mg intravenously once every 3 weeks. In phase II, all patients received LBL-007 at the recommended phase II dose (RP2D) and toripalimab 240 mg intravenously once every 3 weeks. The primary end points were safety in phase Ib and objective response rate (ORR) in phase II. The exploratory end point was the predictive capability of LAG-3 and PD-L1 expression for efficacy.METHODSPatients with advanced tumors refractory to prior standard therapies were enrolled. In phase Ib, patients received LBL-007 200 mg or 400 mg and toripalimab 240 mg intravenously once every 3 weeks. In phase II, all patients received LBL-007 at the recommended phase II dose (RP2D) and toripalimab 240 mg intravenously once every 3 weeks. The primary end points were safety in phase Ib and objective response rate (ORR) in phase II. The exploratory end point was the predictive capability of LAG-3 and PD-L1 expression for efficacy.Between November 30, 2021, and December 1, 2023, 80 patients were enrolled, including 30 (37.5%) with NPC and 50 (62.5%) with other tumors. Median follow-up was 26.0 months. In Phase Ib, LBL-007 was administered at 200 mg to four patients and 400 mg to six patients, with no dose-limiting toxicities observed. Therefore, the 400 mg dose of LBL-007 was established as the RP2D and administered to 70 patients in phase II. Nine (11.3%) of 80 patients had grade 3 or 4 treatment-related adverse events, the most common of which included anemia (2.5%), hyponatremia (2.5%), increased alanine aminotransferase (2.5%), increased aspartate aminotransferase (1.3%), and fatigue (1.3%). Eight patients (10.0%) had treatment-related serious adverse events. No treatment-related deaths were reported. In immunotherapy-naive NPC patients (n = 12), ORR was 33.3%, disease control rate (DCR) was 75%, and median progression-free survival (PFS) was 10.8 months (95% CI, 1.3 to not estimated). In IO-treated NPC patients (n = 17), ORR was 11.8%, DCR was 64.7%, and median PFS was 2.7 months (95% CI, 1.4 to 4.9). For other tumors, ORRs were 15.8% in immunotherapy-naive patients and 3.7% in immunotherapy-treated patients. Patients with ≥ 2 + LAG-3 expression had a higher ORR of 28.0%, compared to 7.7% in those with < 2 + LAG-3 expression.RESULTSBetween November 30, 2021, and December 1, 2023, 80 patients were enrolled, including 30 (37.5%) with NPC and 50 (62.5%) with other tumors. Median follow-up was 26.0 months. In Phase Ib, LBL-007 was administered at 200 mg to four patients and 400 mg to six patients, with no dose-limiting toxicities observed. Therefore, the 400 mg dose of LBL-007 was established as the RP2D and administered to 70 patients in phase II. Nine (11.3%) of 80 patients had grade 3 or 4 treatment-related adverse events, the most common of which included anemia (2.5%), hyponatremia (2.5%), increased alanine aminotransferase (2.5%), increased aspartate aminotransferase (1.3%), and fatigue (1.3%). Eight patients (10.0%) had treatment-related serious adverse events. No treatment-related deaths were reported. In immunotherapy-naive NPC patients (n = 12), ORR was 33.3%, disease control rate (DCR) was 75%, and median progression-free survival (PFS) was 10.8 months (95% CI, 1.3 to not estimated). In IO-treated NPC patients (n = 17), ORR was 11.8%, DCR was 64.7%, and median PFS was 2.7 months (95% CI, 1.4 to 4.9). For other tumors, ORRs were 15.8% in immunotherapy-naive patients and 3.7% in immunotherapy-treated patients. Patients with ≥ 2 + LAG-3 expression had a higher ORR of 28.0%, compared to 7.7% in those with < 2 + LAG-3 expression.LBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies.CONCLUSIONLBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies. Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors. Patients with advanced tumors refractory to prior standard therapies were enrolled. In phase Ib, patients received LBL-007 200 mg or 400 mg and toripalimab 240 mg intravenously once every 3 weeks. In phase II, all patients received LBL-007 at the recommended phase II dose (RP2D) and toripalimab 240 mg intravenously once every 3 weeks. The primary end points were safety in phase Ib and objective response rate (ORR) in phase II. The exploratory end point was the predictive capability of LAG-3 and PD-L1 expression for efficacy. Between November 30, 2021, and December 1, 2023, 80 patients were enrolled, including 30 (37.5%) with NPC and 50 (62.5%) with other tumors. Median follow-up was 26.0 months. In Phase Ib, LBL-007 was administered at 200 mg to four patients and 400 mg to six patients, with no dose-limiting toxicities observed. Therefore, the 400 mg dose of LBL-007 was established as the RP2D and administered to 70 patients in phase II. Nine (11.3%) of 80 patients had grade 3 or 4 treatment-related adverse events, the most common of which included anemia (2.5%), hyponatremia (2.5%), increased alanine aminotransferase (2.5%), increased aspartate aminotransferase (1.3%), and fatigue (1.3%). Eight patients (10.0%) had treatment-related serious adverse events. No treatment-related deaths were reported. In immunotherapy-naive NPC patients (n = 12), ORR was 33.3%, disease control rate (DCR) was 75%, and median progression-free survival (PFS) was 10.8 months (95% CI, 1.3 to not estimated). In IO-treated NPC patients (n = 17), ORR was 11.8%, DCR was 64.7%, and median PFS was 2.7 months (95% CI, 1.4 to 4.9). For other tumors, ORRs were 15.8% in immunotherapy-naive patients and 3.7% in immunotherapy-treated patients. Patients with ≥ 2 + LAG-3 expression had a higher ORR of 28.0%, compared to 7.7% in those with < 2 + LAG-3 expression. LBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies. Abstract Purpose Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors. Methods Patients with advanced tumors refractory to prior standard therapies were enrolled. In phase Ib, patients received LBL-007 200 mg or 400 mg and toripalimab 240 mg intravenously once every 3 weeks. In phase II, all patients received LBL-007 at the recommended phase II dose (RP2D) and toripalimab 240 mg intravenously once every 3 weeks. The primary end points were safety in phase Ib and objective response rate (ORR) in phase II. The exploratory end point was the predictive capability of LAG-3 and PD-L1 expression for efficacy. Results Between November 30, 2021, and December 1, 2023, 80 patients were enrolled, including 30 (37.5%) with NPC and 50 (62.5%) with other tumors. Median follow-up was 26.0 months. In Phase Ib, LBL-007 was administered at 200 mg to four patients and 400 mg to six patients, with no dose-limiting toxicities observed. Therefore, the 400 mg dose of LBL-007 was established as the RP2D and administered to 70 patients in phase II. Nine (11.3%) of 80 patients had grade 3 or 4 treatment-related adverse events, the most common of which included anemia (2.5%), hyponatremia (2.5%), increased alanine aminotransferase (2.5%), increased aspartate aminotransferase (1.3%), and fatigue (1.3%). Eight patients (10.0%) had treatment-related serious adverse events. No treatment-related deaths were reported. In immunotherapy-naive NPC patients (n = 12), ORR was 33.3%, disease control rate (DCR) was 75%, and median progression-free survival (PFS) was 10.8 months (95% CI, 1.3 to not estimated). In IO-treated NPC patients (n = 17), ORR was 11.8%, DCR was 64.7%, and median PFS was 2.7 months (95% CI, 1.4 to 4.9). For other tumors, ORRs were 15.8% in immunotherapy-naive patients and 3.7% in immunotherapy-treated patients. Patients with ≥ 2 + LAG-3 expression had a higher ORR of 28.0%, compared to 7.7% in those with < 2 + LAG-3 expression. Conclusion LBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies. Purpose Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors. Methods Patients with advanced tumors refractory to prior standard therapies were enrolled. In phase Ib, patients received LBL-007 200 mg or 400 mg and toripalimab 240 mg intravenously once every 3 weeks. In phase II, all patients received LBL-007 at the recommended phase II dose (RP2D) and toripalimab 240 mg intravenously once every 3 weeks. The primary end points were safety in phase Ib and objective response rate (ORR) in phase II. The exploratory end point was the predictive capability of LAG-3 and PD-L1 expression for efficacy. Results Between November 30, 2021, and December 1, 2023, 80 patients were enrolled, including 30 (37.5%) with NPC and 50 (62.5%) with other tumors. Median follow-up was 26.0 months. In Phase Ib, LBL-007 was administered at 200 mg to four patients and 400 mg to six patients, with no dose-limiting toxicities observed. Therefore, the 400 mg dose of LBL-007 was established as the RP2D and administered to 70 patients in phase II. Nine (11.3%) of 80 patients had grade 3 or 4 treatment-related adverse events, the most common of which included anemia (2.5%), hyponatremia (2.5%), increased alanine aminotransferase (2.5%), increased aspartate aminotransferase (1.3%), and fatigue (1.3%). Eight patients (10.0%) had treatment-related serious adverse events. No treatment-related deaths were reported. In immunotherapy-naive NPC patients (n = 12), ORR was 33.3%, disease control rate (DCR) was 75%, and median progression-free survival (PFS) was 10.8 months (95% CI, 1.3 to not estimated). In IO-treated NPC patients (n = 17), ORR was 11.8%, DCR was 64.7%, and median PFS was 2.7 months (95% CI, 1.4 to 4.9). For other tumors, ORRs were 15.8% in immunotherapy-naive patients and 3.7% in immunotherapy-treated patients. Patients with [greater than or equal to] 2 + LAG-3 expression had a higher ORR of 28.0%, compared to 7.7% in those with < 2 + LAG-3 expression. Conclusion LBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies. Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors. Between November 30, 2021, and December 1, 2023, 80 patients were enrolled, including 30 (37.5%) with NPC and 50 (62.5%) with other tumors. Median follow-up was 26.0 months. In Phase Ib, LBL-007 was administered at 200 mg to four patients and 400 mg to six patients, with no dose-limiting toxicities observed. Therefore, the 400 mg dose of LBL-007 was established as the RP2D and administered to 70 patients in phase II. Nine (11.3%) of 80 patients had grade 3 or 4 treatment-related adverse events, the most common of which included anemia (2.5%), hyponatremia (2.5%), increased alanine aminotransferase (2.5%), increased aspartate aminotransferase (1.3%), and fatigue (1.3%). Eight patients (10.0%) had treatment-related serious adverse events. No treatment-related deaths were reported. In immunotherapy-naive NPC patients (n = 12), ORR was 33.3%, disease control rate (DCR) was 75%, and median progression-free survival (PFS) was 10.8 months (95% CI, 1.3 to not estimated). In IO-treated NPC patients (n = 17), ORR was 11.8%, DCR was 64.7%, and median PFS was 2.7 months (95% CI, 1.4 to 4.9). For other tumors, ORRs were 15.8% in immunotherapy-naive patients and 3.7% in immunotherapy-treated patients. Patients with [greater than or equal to] 2 + LAG-3 expression had a higher ORR of 28.0%, compared to 7.7% in those with < 2 + LAG-3 expression. LBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies. |
| Audience | Academic |
| Author | Sun, Dong-Chen Yang, Yun-Peng Wang, Wei Hu, De-Sheng Wang, Zhen Zhang, Li Ba, Yi Huang, Yan Zhou, Ting Zhao, Yuan-Yuan Zhao, Hong-Yun Fang, Wen-Feng Wang, Hui-Li Zhang, Ya-Xiong Lin, Jin-Guan Cai, Sheng-Li Chen, Gang Li, Gui-Ling Fu, Zhi-Chao Luo, Su-Xia Deng, Chao Zhu, Hai-Sheng Kang, Xiao-Qiang |
| Author_xml | – sequence: 1 givenname: Gang surname: Chen fullname: Chen, Gang organization: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China – sequence: 2 givenname: Dong-Chen surname: Sun fullname: Sun, Dong-Chen organization: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China – sequence: 3 givenname: Yi surname: Ba fullname: Ba, Yi organization: Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P.R. China – sequence: 4 givenname: Ya-Xiong surname: Zhang fullname: Zhang, Ya-Xiong organization: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China – sequence: 5 givenname: Ting surname: Zhou fullname: Zhou, Ting organization: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China – sequence: 6 givenname: Yuan-Yuan surname: Zhao fullname: Zhao, Yuan-Yuan organization: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China – sequence: 7 givenname: Hong-Yun surname: Zhao fullname: Zhao, Hong-Yun organization: Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China – sequence: 8 givenname: Wen-Feng surname: Fang fullname: Fang, Wen-Feng organization: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China – sequence: 9 givenname: Yan surname: Huang fullname: Huang, Yan organization: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China – sequence: 10 givenname: Zhen surname: Wang fullname: Wang, Zhen organization: Department of Oncology, Linyi Cancer Hospital, Linyi, P.R. China – sequence: 11 givenname: Chao surname: Deng fullname: Deng, Chao organization: Cancer Center, Chong Qing University Three Gorges Hospital, Chongqing, P.R. China – sequence: 12 givenname: De-Sheng surname: Hu fullname: Hu, De-Sheng organization: Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, P.R. China – sequence: 13 givenname: Wei surname: Wang fullname: Wang, Wei organization: Hunan Cancer Hospital, Changsha, P.R. China – sequence: 14 givenname: Jin-Guan surname: Lin fullname: Lin, Jin-Guan organization: Hunan Cancer Hospital, Changsha, P.R. China – sequence: 15 givenname: Gui-Ling surname: Li fullname: Li, Gui-Ling organization: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China – sequence: 16 givenname: Su-Xia surname: Luo fullname: Luo, Su-Xia organization: Department of Oncology, Henan Cancer Hospital, Zhengzhou, P.R. China – sequence: 17 givenname: Zhi-Chao surname: Fu fullname: Fu, Zhi-Chao organization: Department of Radiotherapy, No. 900 Hospital of the PLA Joint Logistics Support Force, Fuzhou, P.R. China – sequence: 18 givenname: Hai-Sheng surname: Zhu fullname: Zhu, Hai-Sheng organization: Department of Oncology, The First People's Hospital of Yulin, Yulin, P.R. China – sequence: 19 givenname: Hui-Li surname: Wang fullname: Wang, Hui-Li organization: Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, China – sequence: 20 givenname: Sheng-Li surname: Cai fullname: Cai, Sheng-Li organization: Nanjing Leads Biolabs Co., Ltd., Nanjing, P.R. China – sequence: 21 givenname: Xiao-Qiang surname: Kang fullname: Kang, Xiao-Qiang organization: Nanjing Leads Biolabs Co., Ltd., Nanjing, P.R. China – sequence: 22 givenname: Li surname: Zhang fullname: Zhang, Li organization: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China – sequence: 23 givenname: Yun-Peng surname: Yang fullname: Yang, Yun-Peng email: yangyp@sysucc.org.cn, yangyp@sysucc.org.cn organization: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. yangyp@sysucc.org.cn |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39920751$$D View this record in MEDLINE/PubMed |
| BookMark | eNptUtuKFDEQbWTFvegP-CABQXzY3k06naTji4yrrgMD-qDPTXWSnsmQTtqke2F-ya80e9GdEQmhilOnTlKX0-LIB2-K4iXBF4Q0_DIRimtW4ipfwjkv-ZPihAjGy0ZU1dGef1ycprTFmBNZ4WfFMZXZCkZOil8LP9lytbguKYLsdkHv0OrDqsRYoNHN6Q4tv30syWN8CtGO4OwAHbIegb4Br4xGHlIYNxB3fm3AIQVRWR8GyJkahWljIkrBWY2meQgxvcs4CqPxpYPOuHM0zG6yyvjJxHOUhZJBy-5yuURTtOCeF097cMm8eLBnxY_Pn75ffSlXX6-XV4tVqRmmU6mVZA1npiY1KAOEdVj0uBJNTQwRfV_1WAohJTWVaXSvOeO1VkJoxVWjpaJnxfJeVwfYtmPMZcZdG8C2d0CI6xZi_qczLWedxBwD9ELWteEdgKqpqWUFlBreZ63391rj3A1G39YWwR2IHka83bTrcNPmAWPOKpkV3j4oxPBzNmlqB5uUcQ68CXNqKeE1Z4xLkamv_6Fuwxx97lVLK0waiTEjj6w15Aqs70N-WN2Ktoum4ryRssGZdfEfVj7aDFblPextxg8S3uwlbPL8p00e9jzZ4NMh8dV-S_724s9O0t8zCuQe |
| ContentType | Journal Article |
| Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
| Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
| DBID | CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13045-025-01666-6 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Proquest Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-8722 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_65b9060aaf7944e6baac43e492a33e6f PMC11806529 A826689980 39920751 |
| Genre | Multicenter Study Clinical Trial, Phase II Clinical Trial, Phase I Journal Article |
| GrantInformation_xml | – fundername: China Postdoctoral Science Foundation grantid: GZB20240900 – fundername: National Natural Science Foundation of China grantid: 82241232 |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M~E NPM O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP ~8M PMFND 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. M48 PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-d503t-dc95865e414acea15b07f027841e17ff2f0977993e2e8dfd6564dc77dc6c8d9c3 |
| IEDL.DBID | 7X7 |
| ISSN | 1756-8722 |
| IngestDate | Wed Aug 27 01:23:42 EDT 2025 Thu Aug 21 18:38:21 EDT 2025 Fri Jul 11 03:50:58 EDT 2025 Fri Jul 25 10:48:42 EDT 2025 Tue Jun 17 21:58:07 EDT 2025 Tue Jun 10 20:55:59 EDT 2025 Thu May 22 21:25:25 EDT 2025 Sat May 10 01:40:54 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-d503t-dc95865e414acea15b07f027841e17ff2f0977993e2e8dfd6564dc77dc6c8d9c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3201890051?pq-origsite=%requestingapplication% |
| PMID | 39920751 |
| PQID | 3201890051 |
| PQPubID | 54946 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_65b9060aaf7944e6baac43e492a33e6f pubmedcentral_primary_oai_pubmedcentral_nih_gov_11806529 proquest_miscellaneous_3164655697 proquest_journals_3201890051 gale_infotracmisc_A826689980 gale_infotracacademiconefile_A826689980 gale_healthsolutions_A826689980 pubmed_primary_39920751 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-02-07 |
| PublicationDateYYYYMMDD | 2025-02-07 |
| PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of hematology and oncology |
| PublicationTitleAlternate | J Hematol Oncol |
| PublicationYear | 2025 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| SSID | ssj0061920 |
| Score | 2.3942297 |
| Snippet | Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients... Purpose Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in... PurposeOpen-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in... Abstract Purpose Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1... |
| SourceID | doaj pubmedcentral proquest gale pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 15 |
| SubjectTerms | Adult Adverse events Aged Alanine transaminase Antibodies Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antigens, CD - immunology Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Aspartate Aspartate aminotransferase Biomarkers Cancer Carcinoma CD223 antigen Combination therapy Consent Disease control Esophageal cancer FDA approval Female Humans Hyponatremia Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Lung cancer Lymphocyte Activation Gene 3 Protein Lymphocytes Male Medical research Medicine, Experimental Melanoma Middle Aged Nasopharyngeal carcinoma Nasopharyngeal Carcinoma - drug therapy Nasopharyngeal Carcinoma - pathology Nasopharyngeal Neoplasms - drug therapy Neoplasms - drug therapy Patients PD-1 protein PD-L1 protein Product development Programmed Cell Death 1 Receptor - antagonists & inhibitors Solid tumors Squamous cell carcinoma Toxicity Tumors Viral antibodies |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4s1CASMhcam1ediOzW0LlC7aIg5U6i1ybKdE6jqrTfbQv8SvZCaPZSMOXLj6pcT-xv4sz3xDyDsdu8QL5RjKeTGuTMaMVZbJwnCl46KMHUYjX3yT55f865W4Okj1hT5hvTxwP3FzKQodyciYEpDDPYxhLE8914lJUy9L3H3hzBsvU_0ejLeCaAyRUXLexPggyDB1a4TvZGyU6P97Iz44iaZekgfHztkDcn_gi3TRf-dDcseHR-TuxfAi_pj8WoS2YqvFF5ZSmKSqqN0tXZ2uGJzKdHOza7pS9v0Ti__UozDIBgj42hS0CnT0A6DBYFIDs70N18AfqcU8Q6FeG-jpaBeqRQGqlaPtbl1vmw9QTjH9FgMo-ZsT2nkn4o_47QmFgRpPl8V8uaRdbpAn5PLs84-P52zIv8CciNKWOauFksLzmBvrTSyKKCv7l0ofZ2WZlBGwRyA4PvHKlQ6oIXc2y5yVVjlt06fkKNTBPye0THAAJTLuHU8KbzLjUodkwxhttJ6RU1yOfNNLbOQoet0VABTyAQr5v6AwI29wMfM-gnRvuvkCrlAS75XRjLzvWqDxwppaM8QgwEeiDNak5fGkJRidnVaPgMkHo2_yFMiU0rjNzcjbfTX2REe24OsdtEE9NyGkzmbkWY-v_U-jRjAwOOitJsibzMq0JlQ_O0lwFPKTItEv_sc8viT3ks5U0C_5mBy1251_BdSrLV53VvYbu8guAQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39920751 https://www.proquest.com/docview/3201890051 https://www.proquest.com/docview/3164655697 https://pubmed.ncbi.nlm.nih.gov/PMC11806529 https://doaj.org/article/65b9060aaf7944e6baac43e492a33e6f |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgkxAviG_KRjESEi-zmg_HiXlBKWysVTdNwKS-RY7tjEpr0jXtw_4l_krunKRbhMRTJH9EiX1n_-y7-x0hH6VvAhslhiGdF-OJipnSiWYiVzyRfl74BqORz87F6SWfzqN5e-FWt26V3ZroFmpTabwjH4WwUyUSZejL6oZh1ii0rrYpNB6SfaQuQ5eueL47cOHZwOsCZRIxqn00CzJM4OqhtYx1RP3_Lsf39qO-r-S9zefkKXnSokaaNtP8jDyw5XPy6Ky1i78gf9Jys2Cz9DsLKQzVIq_MLZ2NZwz2Zrq63taulF18Y_5dPdKDrACGL1VOFyXtvAFoqTC1gVrflleAIqnGbENltVTQ01AXsEVBYBeGbrbLal1_hnKKSbgYCJS9PqLORxF_xK6PKLyotnSSjyYT6jKEvCSXJ8e_vp6yNgsDM5EXbpjRMLAistznSlvlR7kXF4290vpxUQSFBxgSYI4NbGIKAwCRGx3HRgudGKnDV2SvrEr7htAiwBckUcyt4UFuVaxMaBByKCWVlAMyxunIVg3RRobU166gWl9lrSZlIsqlJzylClhKuAWhUpqHlstAhaEVxYC8x8nMmjjSnQJnKRykBJ4uvQH55FqgCsOcatVGIsBHIhlWr-VhryWonu5XdwKTtapfZ3eCOiAfdtXYE93ZSlttoQ2yukWRkPGAvG7ka_fTyBQMOA56Jz3J641Kv6Zc_HbE4EjnJ6JAvv3_dx2Qx4FTAvQ7PiR7m_XWvgNotcmHTn-GZD9Npz-n8Bwfn1_8GLqLir9rQikP |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BqdBLwg7hQGMxKIl1nNxU5iJIRattGydprQJu0tc2xnVFqT0rRC_SUe-EbOyaVbhMTbXn2TnXPPuRHyTrrGsyIyDMt5MR6pkCkdaRYkikfSTVLXYDby5DgYnvFv5-J8i_xpcmEwrLLhiSWjNrnGf-Q9HyRVJBGHPs9_Muwahd7VpoVGhRZHdv0LTLbi02gf4Pve8w4PTr8MWd1VgBnh-EtmtBRRICx3udJWuSJxwrTyv1k3TFMvdUAnArFtPRuZ1IDCw40OQ6MDHRmpfTj3DtnmPpgyHbI9ODg--d7wfrRGnCY1Jwp6hYuOSIYtYx30z7GmNcC_AuCGBGxHZ94Qd4cPyYNaT6X9CrEekS2bPSZ3J7Un_gn53c-WUzbuf2U-BeBMk9ys6XgwZqAN0PnVqihH2ck-c6_nsSDJHBT_mUroNKNN_AHNFDZTUIt1dgl6K9XY3yjLZwp2GlqmiFEgkamhy9UsXxQfYZxi2y8GKGyv9mgZFYkPsYs9CgcVlo6S3mhEy54kT8nZrUDoGelkeWZfEJp6eEAkQm4N9xKrQmV8g0qOUlJJ2SUDBEc8r0p7xFhsuxzIF5dxTbtxIBLpBI5SKTAvbgGNlea-5dJTvm-DtEt2EZhxlbm6YRlxH0y3AO1Zp0s-lCuQaQBMtapzH-CSWH6rtXKntRKIXbenG4SJa2ZTxNek0SVvN9O4EwPoMpuvYA3WkRMikGGXPK_wa_NorE0MmiPsjlqY1_oq7Zls-qMsRY4FBAPhyZf_v9cuuTc8nYzj8ej46BW575UEgVHPO6SzXKzsa1DslsmbmpooubhtAv4LtG5joQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-LAG-3+antibody+LBL-007+plus+anti-PD-1+antibody+toripalimab+in+advanced+nasopharyngeal+carcinoma+and+other+solid+tumors%3A+an+open-label%2C+multicenter%2C+phase+Ib%2FII+trial&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Chen%2C+Gang&rft.au=Dong-Chen%2C+Sun&rft.au=Ba%2C+Yi&rft.au=Ya-Xiong%2C+Zhang&rft.date=2025-02-07&rft.pub=BioMed+Central&rft.eissn=1756-8722&rft.volume=18&rft.spage=1&rft_id=info:doi/10.1186%2Fs13045-025-01666-6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon |